Source: Cancer Research. Unidades: IFSC, IB, FM, ICB
Subjects: NEOPLASIAS PROSTÁTICAS, GENÉTICA MÉDICA, ONCOLOGIA
ABNT
IUGHETTI, P et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Research, v. 61, n. 20, p. 7375-7378, 2001Tradução . . Acesso em: 15 ago. 2022.APA
Iughetti, P., Suzuki, O., Godoi, P. H. C., Alves, V. A. F., Sertie, A. L., Zorick, T., et al. (2001). A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Research, 61( 20), 7375-7378.NLM
Iughetti P, Suzuki O, Godoi PHC, Alves VAF, Sertie AL, Zorick T, Soares F, Camargo A, Moreira ES, Di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno MR. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Research. 2001 ;61( 20): 7375-7378.[citado 2022 ago. 15 ]Vancouver
Iughetti P, Suzuki O, Godoi PHC, Alves VAF, Sertie AL, Zorick T, Soares F, Camargo A, Moreira ES, Di Loreto C, Moreira-Filho CA, Simpson A, Oliva G, Passos-Bueno MR. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Research. 2001 ;61( 20): 7375-7378.[citado 2022 ago. 15 ]